Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium

Pterygium of the Conjunctiva and Cornea Clinical Trial

Official title: A Pilot Study of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium

Status Completed

Clinical Trial Summary

Hypothesis: Subconjunctival bevacizumab injection may potentially suppress neovascularization in pterygium, preventing or retarding the progression of recurrence.

Clinical Trial Description

1. Impending recurrent pterygium

2. Anti-VEGF therapy

• Bevacizumab

• Subconjunctival injection

• Suppress neovascularization ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Pterygium
• Pterygium of the Conjunctiva and Cornea

• NCT number: NCT01288404
• Study type: Interventional
• Source: Ramathibodi Hospital
• Status: Completed
• Phase: N/A
• Start date: January 2008
• Completion date: November 2010